Opposing Digits

MAR. 15 2:53 P.M. ET Shares of Cephalon Inc. dropped Wednesday on concerns an internal Food and Drug Administration memo about the drug maker's attention deficit treatment candidate Sparlon could spell problems for the company in an upcoming advisory panel meeting.

Cephalon shares were down $3.58, or 4.4 percent, to $77.76 in afternoon trading on the Nasdaq at nearly double their average volume, after being down as much as 7 percent earlier in the day. Shares reached a 52-week high of $82.92 Monday after climbing from a year low of $37.35 in June.

# posted by madthumbs @ 11:30 AM